03:23am Wednesday 13 December 2017

Mayo Researchers Find Drug-Resistant HIV Patients With Unimpaired Immune Cells

The findings appear in the online journal PLoS Pathogens.

The goal of current treatments for HIV is to block the virus from reproducing, thereby allowing the immune system to repair itself. These findings show for the first time that not all HIV viruses are equally bad for the immune system. Patients who harbor these viruses do not develop certain complications of the disease because of mutations that render some HIV drugs ineffective — but also impair the ability of the virus to cause disease.

“These findings suggest — in contrast to how these patients have been treated in the past — that changing treatments might not be needed in order to help the immune system,” says Andrew Badley, M.D., Mayo infectious disease researcher and senior author of the study.

 

Background

 

HIV causes disease by progressively killing CD4 T cells, whose function is to orchestrate the immune system. Loss of these cells renders patients susceptible to unusual infections and cancers. Over time, HIV mutates and can become resistant to the drugs used for treatment. Mayo researchers have discovered that viruses with certain mutations that render a component of the drug cocktail used to treat HIV infection ineffective also have an impaired ability to kill CD4 T cells. Even though mutated viruses replicate as well as normal HIV, they fail to cause the infected cells to die. Not all mutant viruses share this effect; only selected mutations cause the impairment in cell killing, without effecting virus replication.

HIV has evolved many ways to cause the death of CD4 T cells, most of which involve HIV accelerating the normal cell death. One kind of cell death that is unique to HIV involves the HIV enzyme protease, whose normal job is to cut up viral proteins so they can be used. This same process also cuts a normal cell protein which creates a novel protein called Casp8p41. This protein is only created during HIV infection. Casp8p41 in turn is responsible for the death of many of the infected cells. Researchers found that cells infected with HIV that also contain the mutations, produced less Casp8p41, and therefore fewer of the infected cells died.

 

Significance of the Findings

 

The current treatment for HIV involves measuring virus levels in the blood and using drugs to stop that virus from reproducing. When drugs stop working, virus levels in the blood rise and physicians typically respond by changing medications. However, effective drugs may not always be available.

“Results from the current study suggest that if a patient is failing their current treatment, and other effective drugs are not available, then it may be best to take advantage of the virus’ lessened ability to kill CD4 T cells, by staying on the same medication” says Dr. Badley. “We have begun to study whether the best approach might be instead to monitor Casp8p41 levels as opposed to measuring virus levels, and use that to determine whether or not to change treatment.”

Researchers have already developed a way to measure Casp8p41 in the blood of patients, and this new knowledge may ultimately lead to a new diagnostic tool for HIV treatment, based upon predicting whether a patient’s virus will deplete CD4 T cells.

Other researchers on the team are first author Sekar Natesampillai, Ph.D.; Zilin Nie M.D.; Nathan Cummins, M.D.; and Gary Bren, of Mayo Clinic; and Dirk Jochmans, Ph.D., Tibotec BVBA, Belgium; and Jonathan Angel, M.D., Ottawa Hospital, Canada. The research was supported by the National Institutes of Health.

###

About Mayo Clinic

Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy of “the needs of the patient come first.” More than 3,700 physicians, scientists and researchers, and 50,100 allied health staff work at Mayo Clinic, which has campuses in Rochester, Minn; Jacksonville, Fla; and Scottsdale/Phoenix, Ariz.; and community-based providers in more than 70 locations in southern Minnesota., western Wisconsin and northeast Iowa. These locations treat more than half a million people each year. To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. For information about research and education, visit www.mayo.edu. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories.


Share on:
or:

MORE FROM Immune System

Health news